Clinical Trial
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Study acronym: STELLAR-316
Not Yet Recruiting
Phase 3
View on ClinicalTrials.gov →
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + MK-3475A and zanzalintinib alone compared with placebo.
| NCT Number |
NCT07750158 |
| Lead Sponsor |
Exelixis
Collaborators: Merck Sharp & Dohme LLC |
| Conditions |
Colorectal Cancer |
| Enrollment |
600 participants |
| Start Date |
2026-08-06 |
| Primary Completion |
2030-04-05 (estimated) |
| Study Completion |
2030-04-05 (estimated) |
| Updated on ClinicalTrials.gov |
2026-08-06 |